Peter Slavin

About Peter Slavin

Peter L. Slavin, MD (age 67 as of Mar 31, 2025) is an independent Class III director at Amwell (AMWL), serving on the board since 2016. He is President & CEO of Cedars‑Sinai Medical Center and Health System (since Oct 1, 2024), an Operating Partner at Advent International (since 2022), and a senior advisor/advisory board member at Arsenal Capital Partners; he previously served as President of Massachusetts General Hospital (2003–2021). Dr. Slavin holds degrees from Harvard College (1979), Harvard Medical School (1984), and Harvard Business School (1990), and teaches health care management at Harvard Medical School as a Professor of Health Care Policy . The board has affirmatively determined he is independent under NYSE rules .

Past Roles

External Roles

Board Governance

• Committee assignments (current): Compensation Committee – Member; Nominating & Corporate Governance Committee – Member . Notably, the 2025 Compensation Committee Report lists “Dr. Peter Slavin, Chairman,” indicating he chaired the committee in connection with the report, though the committee roster table shows Stephen Schlegel as Chair at the proxy date .
• Prior committee leadership (2024 proxy): Compensation Committee – Chair; Nominating & Corporate Governance Committee – Chair .
• Independence: Board determined Dr. Slavin is independent under NYSE rules .
• Attendance: In 2024, the Board held 10 meetings; the Audit and Compensation Committees each met 6 times; Nominating & Governance met 2 times. Each director attended at least 75% of applicable meetings; all directors attended the 2024 annual meeting .
• Board structure: Chair/CEO roles combined (Ido Schoenberg). No Lead Independent Director; independent directors meet in regular executive session with a rotating presiding director .
• Controlled company: Founders control 51% voting power; company states it does not rely on NYSE controlled company exemptions—majority of directors and all committees are independent .
• Risk oversight: Board oversees strategic risk; Audit monitors financial, compliance, cyber, and related‑party risk; Compensation monitors pay‑risk; Nominating & Governance oversees governance/ESG .
• Anti‑hedging/pledging: Directors are prohibited from hedging or pledging company stock .

Fixed Compensation

Notes:

• The $85,000 in both FY 2023 and FY 2024 aligns with policy and his committee chair roles noted in the 2024 proxy (Chair of both Compensation and Nominating & Governance) .

Performance Compensation

The company’s pay program for executives received ~98% Say‑on‑Pay support at the 2024 annual meeting, signaling broad shareholder alignment on compensation governance .

Other Directorships & Interlocks

Expertise & Qualifications

• Healthcare and medical operational expertise; Academics & Research; Corporate Governance; Strategy & M&A (as reflected in the board’s skills matrix) .
• Tenured health‑system operator (MGH President 18 years) and current large health‑system CEO (Cedars‑Sinai) .

Equity Ownership

Governance Assessment

• Strengths

  • Deep healthcare operating expertise and academic credibility; independent status confirmed by the board .
  • Robust director pay structure emphasizing equity; anti‑hedging/pledging and director ownership guidelines support alignment .
  • Strong investor support for compensation practices (~98% Say‑on‑Pay in 2024), suggesting positive external confidence in pay governance .
  • Regular executive sessions of independent directors .

• Watch‑items / potential conflicts

  • Active CEO of a major health system (Cedars‑Sinai) while serving on AMWL’s board could create perceived industry‑relationship sensitivities; however, the board affirmed his independence and disclosed no related‑party transactions involving Dr. Slavin .
  • Controlled company structure without a Lead Independent Director concentrates authority with the Chair/CEO, though AMWL states it does not rely on controlled company exemptions and committees are fully independent .

• Committee leadership signal

  • Committee roles shifted year‑over‑year: Slavin chaired Compensation and Nominating & Governance per the 2024 proxy , while the 2025 roster lists him as a member of both committees . The 2025 Compensation Committee Report is signed “Dr. Peter Slavin, Chairman,” indicating he chaired compensation in connection with the report despite the roster table showing a different chair; investors may seek clarification on timing/transition to maintain transparency .

• Attendance and engagement

  • Meets the company’s attendance threshold (≥75% of meetings) and attended the 2024 annual meeting, supporting engagement .

• Related‑party and policy controls

  • No related‑party transactions involving Dr. Slavin disclosed; company maintains a formal related‑person transaction approval policy overseen by the Audit Committee .

Director Compensation Details (Reference)

Board & Committee Service (Current and Prior)

Overall: Dr. Slavin’s healthcare leadership and governance experience bolster board oversight in a strategically relevant sector. Independence, ownership alignment, and attendance are supportive of investor confidence; governance optics around controlled status and chair transitions warrant continued monitoring .